TDOC Stock Recent News

NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE:TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

New enhancements to the company's Prism care delivery platform connect and assist digital and in-person care teams in coordinating care and driving positive health outcomes New enhancements to the company's Prism care delivery platform connect and assist digital and in-person care teams in coordinating care and driving positive health outcomes

Teladoc Health, Inc. (NYSE:TDOC ) TD Cowen 45th Annual Health Care Results Conference March 3, 2025 10:30 AM ET Company Participants Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Conference Call Participants Charles Rhyee - TD Cowen Charles Rhyee Thank you everyone for being here for the next session here. We're pleased to have Teladoc Health with us today.

NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE:TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Teladoc (TDOC -11.83%) stock is sinking in Thursday's trading on the heels of the company's recent fourth-quarter release. The telehealth specialist's share price was down 11.7% as of 2:45 p.m.

TDOC expects revenues in the Integrated Care segment to witness 0-3% growth on a year-over-year basis.

Teladoc Health, Inc.'s disappointing guidance and lack of revenue growth have led me to adopt a neutral stance on TDOC stock despite its cheap valuation at 7x forward free cash flow. My investment strategy focuses on businesses with strong balance sheets and the potential for significant free cash flow growth, but Teladoc's fundamentals don't align with this narrative. Teladoc's manageable debt and plans to retire convertible debt improve its financial footing, but I need to see revenue momentum before considering it investable again.

NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE:TDOC) Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Teladoc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Teladoc Health, Inc. (NYSE:TDOC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Michael Minchak - Head of Investor Relations Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Conference Call Participants Lisa Gill - J.P. Morgan Jessica Tassan - Piper Sandler David Roman - Goldman Sachs Sean Dodge - RBC Richard Close - Cannacord Genuity Daniel Grosslight - Citi Jailendra Singh - Truist George Hill - Deutsche Bank Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Operator Good afternoon and thank you all for attending the Teladoc Health Q4 2024 Earnings Call.